previous compound ID: 103 next compound
InChIKey: ACWBQPMHZXGDFX-QFIPXVFZSA-N
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O

biological descriptors:

CFTR relevance: unspecified

Category:
Influence on CFTR function unknown
Order of interaction unknown
subcellular compartment unknown

reference list:

ReferenceID: 53
"E Matthes" "JW Hanrahan" "D Rotin" "DY Thomas" "SD Macknight" "GW Carlile" "R Robert" "J Goepp" "J Liao" "B Kus"

chemical graph of compound 103





CID is 60846
synonyms found at PubChem are:
valsartan, 137862-53-4, Diovan, Provas, Tareg, L-Valsartan, CGP 48933, Exforge, Kalpress, Miten, Nisis, Vals, CGP-48933, (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid, Valsarran, Valsartan [USAN:INN], [3H]valsartan, UNII-80M03YXJ7I, Diovan (TN), N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, CHEMBL1069, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, 80M03YXJ7I, CHEBI:9927, 137863-60-6, C24H29N5O3, (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid, (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid, N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine, (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine, L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, walsartan, N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine, Valzaar, Valtan, N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine, N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine, SMR000466318, CEPA brand of valsartan, Lacer brand of valsartan, Sanol brand of valsartan, Esteve brand of valsartan, Aventis brand of valsartan, Schwarz brand of valsartan, Novartis brand of valsartan, cardopan, valsartanin, Prexxartan, Valpression, Varexan, HSDB 7519, (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, Diovan, Valsartan, L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, N-PENTANOYL-N-([2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL)-L-VALINE, Valsartan [USAN:USP:INN:BAN], Valsartan,(S), (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid, (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid, (S)-3-METHYL-2-(PENTANOYL-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMINO)-BUTYRIC ACID, (S)-3-METHYL-2-[N-((4-[2-(2H-1,2,3,4-TETRAZOL-5-YL)PHENYL]PHENYL)METHYL)PENTANAMIDO]BUTANOIC ACID, (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, valsartan (Diovan), Valzaar (TN), Valtan (TN), ANGIOTAN, PubChem9865, Spectrum_001796, AC1Q5QIK, Spectrum2_001120, Spectrum3_001831, Spectrum4_000749, Spectrum5_001582, D04HSR, D06UDG, Prexxartan (oral solution), EC 604-045-2, AC1L1U1M, SCHEMBL2542, BSPBio_003501, GTPL593, KBioGR_001078, KBioSS_002289, MLS000759423, MLS001424088, Valsartan (JAN/USAN/INN), BIDD:GT0345, SPECTRUM1505209, SPBio_001260, GTPL3937, Valsartan (JP17/USAN/INN), Valsartan, >=98% (HPLC), KBio2_002287, KBio2_004855, KBio2_007423, KBio3_003006, KS-00000ISS, EZR-104, VAL-489, ACWBQPMHZXGDFX-QFIPXVFZSA-N, MolPort-002-507-854, MolPort-003-666-608, HMS1922L21, HMS2051L12, HMS2093K22, HMS2232F05, HMS3651E04, HMS3715P12, Pharmakon1600-01505209, ACT02671, BCP05184, ZINC3875259, ANW-49040, BDBM50049186, BG0645, GP8514, MFCD00865840, NSC758927, s1894, AKOS015914315, AKOS015994698, AB07510, AC-4543, AM90287, AN-7255, CCG-101028, CCG-221275, CS-1967, DB00177, DS-1248, KS-1194, MCULE-6728882368, NC00278, NSC-758927, RTR-031794, VA11929, AK-58790, BC204156, BR-58790, CPD000466318, HY-18204, I997, SAM001246581, SC-00971, SBI-0206738.P001, AB0013966, AB2000354, AX8018200, LS-161334, ST2408288, TL8000869, TR-031794, FT-0631156, 4997-EP2270011A1, 4997-EP2272841A1, 4997-EP2277879A1, 4997-EP2295406A1, 4997-EP2295422A2, 4997-EP2298772A1, 4997-EP2298776A1, 4997-EP2298779A1, 4997-EP2301923A1, 4997-EP2301931A1, 4997-EP2301936A1, 4997-EP2305219A1, 4997-EP2308562A2, 4997-EP2308839A1, 62V534, D00400, J10013, S-6418, AB00639940-06, AB00639940-08, AB00639940_09, AB00639940_11, SR-05000001928, J-007068, SR-05000001928-1, BRD-K45158365-001-02-3, BRD-K45158365-001-05-6, I14-41498, Valsartan, European Pharmacopoeia (EP) Reference Standard, N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine, Valsartan, United States Pharmacopeia (USP) Reference Standard, Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material, (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid, (S)-N-BUTYRYL-N-([2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL)-VALINE, 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid, L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI), L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine, N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine, N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine, Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard, Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard, (2S)-3-METHYL-2-(PENTANOYL-[2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMINO)-BUTYRIC ACID, (2S)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid, (s)-3-methyl-2-(pentanoyl-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino)-butyric acid 137862-53-, (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid, (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine, (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine, 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid, 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid